I. Sarkar

The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis

Elizabeth S. Chen, S. Toms, E. Chen, 2021, Journal of Neuro-Oncology.

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

P. Hegde, J. Sosman, F. Hodi, 2019, Clinical Cancer Research.

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

C. Rudin, S. Gettinger, R. Heist, 2016 .

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study

E. Elgabry, L. Molinero, R. Nanda, 2019, JAMA oncology.

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

T. Powles, D. Shaffer, D. Petrylak, 2021, Clinical Cancer Research.

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.

Yulei N. Wang, L. Molinero, L. Emens, 2019, Gynecologic oncology.

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

L. Molinero, F. Kabbinavar, I. Braña, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger, R. Heist, S. Ou, 2018 .

A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.

G. Shapiro, P. LoRusso, H. Burris, 2020, The oncologist.

MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

C. Rudin, S. Gettinger, R. Heist, 2018, Journal of Thoracic Oncology.